Mesa Laboratories Insider Sells Shares Amid Stock Volatility

On June 16, 2026, Archbold Brian David, the Senior Vice President of Operations at Mesa Laboratories, Inc. (NasdaqGS: MLAB), executed a planned sale of 1,151 shares. The shares were sold at an average price of $101.27, amounting to a total value of $116,561.77.

Insider Buying and Selling at Mesa Laboratories, Inc.

Archbold's sale was part of a planned transaction. On the same day, other insiders also sold shares, including CFO John Sakys, who sold 1,223 shares, and CAO Lyndsey Elizabeth Crennen, who sold 118 shares, both at the same average price of $101.27. Notably, on June 15, Sakys and Archbold also made purchases, with Sakys buying 2,717 shares at $104.08, and Archbold acquiring 4,328 shares at no reported price.

Other Institutional Activity in Mesa Laboratories

LONG PATH PARTNERS LP significantly increased its stake in Mesa Laboratories by 178,360 shares, bringing its total to 405,583 shares valued at about $35.86 million. Meanwhile, BLACKROCK, INC. trimmed its position by 4,815 shares, ending with 393,851 shares worth approximately $34.82 million. BOSTON PARTNERS added 55,335 shares, totaling 268,711 shares valued at $23.76 million. SELECT EQUITY GROUP, L.P. also increased its holdings by 29,450 shares, reaching a total of 235,885 shares valued at $20.86 million.

Mesa Laboratories, Inc. Stock Down 26.4%

Shares of Mesa Laboratories trade near $99.68. The company has a market cap of about $550.7 million and a P/E ratio of 82.38, indicating high valuation compared to earnings. Its forward P/E is more conservative at 8.12. The stock has a beta of 0.927, suggesting moderate volatility relative to the market. Over the past year, the stock has ranged from $55.45 to $113.99, with a 50-day moving average of $101.95 and a 200-day moving average of $84.68.

Analysts Set New Price Targets

Analysts have mixed views on Mesa Laboratories. On February 4, 2026, Wells Fargo maintained a 'hold' rating with a price target of $94. The consensus among analysts is a target mean price of $112, based on two opinions.

About Mesa Laboratories

Mesa Laboratories, Inc., headquartered in Lakewood, Colorado, develops and manufactures scientific and technical instruments. It operates in several segments, including sterilization and disinfection control, clinical genomics, biopharmaceutical development, and calibration solutions. The company provides products used in quality control and life sciences tools across various industries. Mesa Laboratories was incorporated in 1982 and employs about 717 people.

Bottom Line

Insider transactions at Mesa Laboratories, including the recent sale by SVP Operations Archbold Brian David, are part of regular activity observed in public companies. Investors keep a close eye on such transactions as they can offer insights into insider sentiment. Institutional interest remains active, with notable adjustments in holdings. The company's stock performance and analyst ratings suggest a complex valuation picture.